Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.